Rezlidhia
Payments companies reported to CMS as associated with Rezlidhia. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Rezlidhia, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Rezlidhia
These are the largest totals companies reported as associated with Rezlidhia. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Joseph Bailes | Mckinney, TX | $168,040.67 | |
| Praneeth Baratam | Charleston, SC | Hematology (Internal Medicine) | $83,583.17 |
| James Mccloskey | Hackensack, NJ | Medical Oncology | $81,686.96 |
| Andrew Rettew | West Reading, PA | Hematology & Oncology | $68,590.81 |
| Slawomir Wojtowicz-Praga | South San Francisco, CA | Medical Oncology | $66,000.00 |
| Delong Liu | Hawthorne, NY | Hematology & Oncology | $64,361.39 |
| Thomas Leblanc | Durham, NC | Medical Oncology | $62,920.70 |
| George Yaghmour | Los Angeles, CA | Hematology & Oncology | $61,530.93 |
| Suresh Ratnam | Mcallen, TX | Medical Oncology | $58,741.08 |
| Satheesh Kathula | Kettering, OH | Hematology & Oncology | $58,439.70 |
Prescribed Rezlidhia?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.